Back
Speaker illustration

Doctor Olena Medentseva

L.T.Malaya Institute of Therapy, Kharkiv (Ukraine)

She studied at the Kharkiv National Medical University, Kharkiv, Ukraine from 2003 to 2009, then she graduated from an internship in the specialty Internal Medicine, in 2017 received a cardiologist specialty. Just finished work on thesis on studying the influence of different risk factors, including genetics, on the population of patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction.

Presentations

ST2 prognostic value of unfavorable heart failure course in diabetic patients with HFpEF, 7.5 years follow-up

Event: Heart Failure 2022

Topic: Epidemiology, Prognosis, Outcome

Session: Heart Failure ePosters - focus on Chronic Heart Failure 1

Access
Thumbnail

Association of soluble ST2, M235T polymorphism of ATG with insulin resistance in diabetic patients with heart failure with preserved ejection fraction

Event: ESC Congress 2021 - The Digital Experience

Topic: Comorbidities

Session: Chronic heart failure e-posters

Access
Thumbnail

Inhibitors of the renin-angiotensin system in diabetic patients with heart failure with preserved ejection fraction treatment: impact of m235t polymorphism of angiotensinogen

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: Novelties in pathophysiology of heart failure with preserved ejection fraction

Access
Thumbnail

M235T polymorphism of ATG: prognostic marker of cardiovascular events in diabetic patients with heart failure with preserved ejection fraction, a 2 year follow-up.

Event: ESC Congress 2018

Topic: Epidemiology, Prognosis, Outcome

Session: Chronic heart failure – Epidemiology, prognosis, outcome

Access
Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb